BMY – Bristol-Myers Squibb Company
Bristol-Myers Squibb CompanyBMY
$58.95Name : Bristol-Myers Squibb Company
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $120,418,025,472.00
EPSttm : 4.54
Bristol-Myers Squibb Company
$58.95
3.60%$2.20
BMY — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
2.06
Margin Of Safety %
27
Put/Call OI Ratio
1.1
EPS Next Q Diff
-0.44
EPS Last/This Y
0.8
EPS This/Next Y
-0.38
Price
61.15
Target Price
66.57
Analyst Recom
2.45
Performance Q
7.85
Upside
-3.5%
Beta
0.2
Ticker: BMY
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-09-08 | BMY | 64.71 | 0.89 | 0.19 | 703765 |
| 2026-09-09 | BMY | 64.4 | 0.88 | 0.51 | 711310 |
| 2026-09-10 | BMY | 63.75 | 0.88 | 4.05 | 712938 |
| 2026-09-11 | BMY | 63.63 | 0.94 | 0.68 | 742090 |
| 2026-09-14 | BMY | 64.1 | 0.95 | 1.24 | 736914 |
| 2026-09-15 | BMY | 63.74 | 0.94 | 1.32 | 739793 |
| 2026-09-16 | BMY | 63.57 | 0.94 | 2.92 | 741061 |
| 2026-09-17 | BMY | 62.83 | 1.00 | 5.93 | 758092 |
| 2026-09-18 | BMY | 63.24 | 1.03 | 0.95 | 773887 |
| 2026-09-21 | BMY | 62.66 | 1.10 | 1.14 | 613641 |
| 2026-09-22 | BMY | 62.33 | 1.10 | 0.61 | 627702 |
| 2026-09-23 | BMY | 61.18 | 1.10 | 0.57 | 635250 |
| 2026-09-24 | BMY | 61.5 | 1.09 | 0.25 | 646362 |
| 2026-09-25 | BMY | 62.7 | 1.06 | 0.26 | 658235 |
| 2026-09-28 | BMY | 63.87 | 1.06 | 0.67 | 666259 |
| 2026-09-29 | BMY | 62.96 | 1.06 | 4.62 | 677554 |
| 2026-09-30 | BMY | 62.42 | 1.08 | 0.71 | 686279 |
| 2026-10-01 | BMY | 61.46 | 1.07 | 0.97 | 691266 |
| 2026-10-02 | BMY | 61.16 | 1.10 | 0.49 | 708328 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-09-08 | BMY | 64.71 | 6.3 | 2721.1 | 6.95 |
| 2026-09-09 | BMY | 64.29 | 6.3 | 3064.9 | 6.95 |
| 2026-09-10 | BMY | 63.75 | 6.3 | 3009.8 | 6.95 |
| 2026-09-11 | BMY | 63.61 | 6.3 | 3117.3 | 6.95 |
| 2026-09-14 | BMY | 64.10 | 6.3 | 3242.7 | 6.95 |
| 2026-09-15 | BMY | 63.74 | 6.3 | 3071.7 | 6.95 |
| 2026-09-16 | BMY | 63.74 | 6.3 | 3071.7 | 6.95 |
| 2026-09-17 | BMY | 62.83 | 6.3 | 2985.3 | 6.95 |
| 2026-09-18 | BMY | 63.03 | 6.3 | 3187.0 | 6.95 |
| 2026-09-21 | BMY | 62.64 | 6.3 | 3058.1 | 6.95 |
| 2026-09-22 | BMY | 62.24 | 6.1 | 3067.0 | 6.95 |
| 2026-09-23 | BMY | 61.18 | 6.1 | 2918.7 | 6.95 |
| 2026-09-24 | BMY | 61.51 | 6.1 | 3223.1 | 6.95 |
| 2026-09-25 | BMY | 62.89 | 6.1 | 3445.0 | 6.95 |
| 2026-09-28 | BMY | 63.88 | 6.1 | 3361.9 | 6.95 |
| 2026-09-29 | BMY | 62.88 | 6.1 | 2936.9 | 6.95 |
| 2026-09-30 | BMY | 62.45 | 6.1 | 3059.9 | 6.95 |
| 2026-10-01 | BMY | 61.46 | 6.1 | 2946.8 | 6.95 |
| 2026-10-02 | BMY | 61.15 | 6.1 | 2881.0 | 6.95 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-09-08 | BMY | -0.46 | 0.85 | 2.25 |
| 2026-09-09 | BMY | -0.46 | 0.85 | 2.25 |
| 2026-09-10 | BMY | -0.46 | 0.85 | 2.25 |
| 2026-09-11 | BMY | -0.56 | 0.85 | 2.16 |
| 2026-09-14 | BMY | -0.56 | 0.84 | 2.16 |
| 2026-09-15 | BMY | -0.56 | 0.84 | 2.16 |
| 2026-09-16 | BMY | -0.56 | 0.84 | 2.16 |
| 2026-09-17 | BMY | -0.56 | 0.84 | 2.16 |
| 2026-09-18 | BMY | -0.56 | 0.84 | 2.16 |
| 2026-09-21 | BMY | -0.56 | 0.87 | 2.16 |
| 2026-09-23 | BMY | -0.56 | 0.87 | 2.16 |
| 2026-09-24 | BMY | -0.56 | 0.87 | 2.16 |
| 2026-09-25 | BMY | -0.56 | 0.87 | 2.06 |
| 2026-09-28 | BMY | -0.56 | 0.87 | 2.06 |
| 2026-09-29 | BMY | -0.56 | 0.87 | 2.06 |
| 2026-09-30 | BMY | -0.56 | 0.87 | 2.06 |
| 2026-10-01 | BMY | -0.56 | 0.87 | 2.06 |
| 2026-10-02 | BMY | -0.56 | 0.87 | 2.06 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.04
Avg. EPS Est. Current Quarter
1.73
Avg. EPS Est. Next Quarter
1.6
Insider Transactions
-0.56
Institutional Transactions
0.87
Beta
0.2
Average Sales Estimate Current Quarter
12661
Average Sales Estimate Next Quarter
12695
Fair Value
77.89
Quality Score
89
Growth Score
52
Sentiment Score
77
Actual DrawDown %
24.9
Max Drawdown 5-Year %
-47.7
Target Price
66.57
P/E
13.47
Forward P/E
9.32
PEG
P/S
2.54
P/B
5.6
P/Free Cash Flow
10.92
EPS
4.54
Average EPS Est. Cur. Y
6.95
EPS Next Y. (Est.)
6.56
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
18.87
Relative Volume
0.87
Return on Equity vs Sector %
15.4
Return on Equity vs Industry %
6
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
2881
◆
BMY
Healthcare
$61.15
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
37.9
Range 1M
8.2%
Sup Dist
0.3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
13.1%
EPS NY
-5.7%
52W%
70.5%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+29.8% upside
Upside
+29.8%
Quality
89
MoS
27%
BMY — P/E HistoricalDrug Manufacturers - General
Bristol-Myers Squibb CompanySector: Healthcare
Industry: Drug Manufacturers - General
Employees: 32500
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
BMY
Latest News
—
Caricamento notizie per BMY…
stock quote shares BMY – Bristol-Myers Squibb Company Stock Price stock today
news today BMY – Bristol-Myers Squibb Company stock forecast ,stock prediction 2023 2024 2025
marketwatch BMY – Bristol-Myers Squibb Company yahoo finance google finance
stock history BMY – Bristol-Myers Squibb Company invest stock market
stock prices BMY premarket after hours
ticker BMY fair value insiders trading